Research programme: antibacterials - Curia/Genentech
Alternative Names: AMR-BAC-1Latest Information Update: 13 Oct 2021
At a glance
- Originator AMRI
- Developer Curia
- Class Anti-infectives; Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 12 Sep 2016 Preclinical development is ongoing in USA (AMRI pipeline, September 2016)
- 05 Jan 2011 Genentech has received an exclusive license from AMRI to develop and commercialise antibacterial candidates identified from AMRI's antibacterial research programme